In this article (Cancer Prev Res 2013;6:1242–50), which was published in the November 2013 issue of Cancer Prevention Research (1), some of the values presented in Table 3 were incorrect due to a coding error in the analysis. The corrected Table 3 and the corresponding Results section with the correct values are below.
HPV16 and HPV18 antibody stability between months 24, 36, and 48 by number of doses
| . | 1-dose . | 2-doses(0/1) . | 2-doses(0/6) . | 3-doses . | P-value . |
|---|---|---|---|---|---|
| 24–48 months n (%) | |||||
| HPV16a | |||||
| Stablec | 68 (87.18) | 128 (91.43) | 43 (82.69) | 106 (88.33) | 0.30 |
| Decreasec | 10 (12.82) | 12 (8.57) | 9 (17.31) | 14 (11.67) | |
| HPV18b | |||||
| Stable | 71 (91.03) | 128 (91.42) | 43 (82.69) | 103 (85.83) | 0.24 |
| Decrease | 7 (8.97) | 12 (8.57) | 9 (17.31) | 17 (14.17) | |
| 36–48 months n (%) | |||||
| HPV16 | |||||
| Stable decrease | 74 (94.87) | 136 (97.14) | 51 (98.08) | 117 (97.50) | 0.69 |
| 4 (5.13) | 4 (2.86) | 1 (1.92) | 3 (2.50) | ||
| HPV18 | |||||
| Stable | 72 (92.31) | 134 (95.71) | 51 (98.08) | 118 (98.33) | 0.15 |
| Decrease | 6 (7.69) | 6 (4.29) | 1 (1.92) | 2 (1.67) | |
| . | 1-dose . | 2-doses(0/1) . | 2-doses(0/6) . | 3-doses . | P-value . |
|---|---|---|---|---|---|
| 24–48 months n (%) | |||||
| HPV16a | |||||
| Stablec | 68 (87.18) | 128 (91.43) | 43 (82.69) | 106 (88.33) | 0.30 |
| Decreasec | 10 (12.82) | 12 (8.57) | 9 (17.31) | 14 (11.67) | |
| HPV18b | |||||
| Stable | 71 (91.03) | 128 (91.42) | 43 (82.69) | 103 (85.83) | 0.24 |
| Decrease | 7 (8.97) | 12 (8.57) | 9 (17.31) | 17 (14.17) | |
| 36–48 months n (%) | |||||
| HPV16 | |||||
| Stable decrease | 74 (94.87) | 136 (97.14) | 51 (98.08) | 117 (97.50) | 0.69 |
| 4 (5.13) | 4 (2.86) | 1 (1.92) | 3 (2.50) | ||
| HPV18 | |||||
| Stable | 72 (92.31) | 134 (95.71) | 51 (98.08) | 118 (98.33) | 0.15 |
| Decrease | 6 (7.69) | 6 (4.29) | 1 (1.92) | 2 (1.67) | |
aHPV16 Spearman's rank correlation coefficient at 24- and 48-month visits was 0.88 (P < 0.0001).
bHPV18 Spearman's rank correlation coefficient at 24- and 48-month visits was 0.90 (P < 0.0001).
cStable antibodies defined as levels that did not decline by 2-fold or more; a decrease in antibodies as those that declined 2-fold or more.
Results
HPV16 and HPV18 antibody durability between 24 to 48 and 36 to 48 months is shown in Table 3. By our definition of less than a 2-fold change, stability between 24 to 48 and 36 to 48 months was high in all dose groups (stability24–48 months in the one dose group: HPV16 = 87%; HPV18 = 91%; stability36–48 months in the one dose group: HPV16 = 95%; HPV18 = 92%; all P values > 0.05 compared with the other dose groups) and only a small proportion of women had a decline in antibody levels observed between 24 to 48 and 36 to 48 months regardless of number of doses.
In addition, the maximum values for HPV16, 3-dose, 90th percentiles were mistakenly presented in Table 1. The correct 90th percentiles are (in the order they appear in the table) below.
Enrollment: 47.32
1: 2,349.73
6: 2,409.74
12: 6,683.96
24: 2,978.55
36: 2,573.65
48: 1,808.36
Finally, in the footnote for Table 4, the cutoff for HPV16 neutralization was incorrect. The correct cutoff for HPV16 neutralization is 25.1.
The authors regret the errors.
RSS Feeds